Telo Ebit vs Income Tax Expense Analysis

TELO Stock

CAD 0.12 0.01 9.09%

Telo Genomics financial indicator trend analysis is much more than just breaking down Telo Genomics Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Telo Genomics Corp is a good investment. Please check the relationship between Telo Genomics Ebit and its Income Tax Expense accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telo Genomics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Ebit vs Income Tax Expense

Ebit vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Telo Genomics Corp Ebit account and Income Tax Expense. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Telo Genomics' Ebit and Income Tax Expense is -0.39. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Telo Genomics Corp, assuming nothing else is changed. The correlation between historical values of Telo Genomics' Ebit and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Telo Genomics Corp are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Ebit i.e., Telo Genomics' Ebit and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

-0.39

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ebit

Income Tax Expense

Most indicators from Telo Genomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Telo Genomics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telo Genomics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Issuance Of Capital Stock is likely to climb to about 3.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1.6 M in 2024.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	57.0K	33.1K	38.1K	55.4K
Research Development	1.1M	1.4M	1.6M	834.8K

Cost Of Revenue Research Development

Telo Genomics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Net Receivables	Common Stock Shares Outstanding	Net Tangible Assets	Accounts Payable	Long Term Debt	Short Long Term Debt	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Other Current Liab	Other Liab	Property Plant And Equipment Net	Non Currrent Assets Other	Other Assets
Total Assets		0.08	0.97	-0.93	-0.73	0.95	-0.31	0.95	0.68	0.11	0.99	0.35	0.82	0.97	-0.13	-0.66	0.43	0.43	0.59	0.79	0.09	-0.11	-0.49	-0.69	-0.57	-0.49
Total Current Liabilities	0.08		-0.19	0.16	-0.47	-0.1	-0.13	-0.1	0.63	1.0	-0.02	0.28	0.31	-0.07	0.91	-0.53	0.23	0.23	0.54	0.35	0.72	0.77	-0.04	-0.26	-0.39	-0.04
Total Stockholder Equity	0.97	-0.19		-0.96	-0.6	0.96	-0.26	0.96	0.5	-0.15	0.98	0.28	0.73	0.97	-0.36	-0.51	0.36	0.36	0.43	0.68	-0.1	-0.31	-0.48	-0.61	-0.45	-0.48
Net Debt	-0.93	0.16	-0.96		0.69	-0.98	0.38	-0.98	-0.44	0.12	-0.97	-0.12	-0.73	-0.95	0.36	0.54	-0.51	-0.51	-0.48	-0.77	0.19	0.18	0.36	0.74	0.61	0.36
Retained Earnings	-0.73	-0.47	-0.6	0.69		-0.73	0.62	-0.73	-0.66	-0.51	-0.73	-0.06	-0.88	-0.69	-0.23	0.86	-0.82	-0.82	-0.81	-0.96	-0.16	-0.47	0.37	0.94	0.94	0.37
Cash	0.95	-0.1	0.96	-0.98	-0.73		-0.42	1.0	0.44	-0.06	0.98	0.1	0.78	0.96	-0.34	-0.58	0.59	0.59	0.49	0.79	-0.21	-0.12	-0.53	-0.78	-0.64	-0.53
Non Current Assets Total	-0.31	-0.13	-0.26	0.38	0.62	-0.42		-0.42	-0.11	-0.16	-0.35	0.38	-0.49	-0.4	0.1	0.38	-0.73	-0.73	-0.33	-0.59	0.26	-0.34	0.28	0.71	0.7	0.28
Cash And Short Term Investments	0.95	-0.1	0.96	-0.98	-0.73	1.0	-0.42		0.44	-0.06	0.98	0.1	0.78	0.96	-0.34	-0.58	0.59	0.59	0.49	0.79	-0.21	-0.12	-0.53	-0.78	-0.64	-0.53
Other Stockholder Equity	0.68	0.63	0.5	-0.44	-0.66	0.44	-0.11	0.44		0.66	0.57	0.61	0.68	0.58	0.52	-0.71	0.15	0.15	0.72	0.66	0.73	0.21	-0.12	-0.42	-0.43	-0.12
Total Liab	0.11	1.0	-0.15	0.12	-0.51	-0.06	-0.16	-0.06	0.66		0.01	0.28	0.34	-0.03	0.9	-0.56	0.26	0.26	0.57	0.39	0.72	0.77	-0.05	-0.3	-0.43	-0.05
Total Current Assets	0.99	-0.02	0.98	-0.97	-0.73	0.98	-0.35	0.98	0.57	0.01		0.25	0.8	0.97	-0.24	-0.63	0.5	0.5	0.55	0.79	-0.05	-0.14	-0.52	-0.73	-0.6	-0.52
Net Receivables	0.35	0.28	0.28	-0.12	-0.06	0.1	0.38	0.1	0.61	0.28	0.25		0.18	0.18	0.47	-0.46	-0.4	-0.4	0.48	0.09	0.73	-0.17	0.03	0.15	0.17	0.03
Common Stock Shares Outstanding	0.82	0.31	0.73	-0.73	-0.88	0.78	-0.49	0.78	0.68	0.34	0.8	0.18		0.8	0.1	-0.78	0.66	0.66	0.7	0.87	0.21	0.32	-0.54	-0.79	-0.72	-0.54
Net Tangible Assets	0.97	-0.07	0.97	-0.95	-0.69	0.96	-0.4	0.96	0.58	-0.03	0.97	0.18	0.8		-0.31	-0.52	0.44	0.44	0.44	0.75	-0.06	-0.2	-0.48	-0.67	-0.54	-0.48
Accounts Payable	-0.13	0.91	-0.36	0.36	-0.23	-0.34	0.1	-0.34	0.52	0.9	-0.24	0.47	0.1	-0.31		-0.47	-0.01	-0.01	0.52	0.12	0.83	0.69	0.18	-0.01	-0.16	0.18
Long Term Debt	-0.66	-0.53	-0.51	0.54	0.86	-0.58	0.38	-0.58	-0.71	-0.56	-0.63	-0.46	-0.78	-0.52	-0.47		-0.61	-0.61	-0.97	-0.84	-0.41	-0.44	0.32	0.76	0.77	0.32
Short Long Term Debt	0.43	0.23	0.36	-0.51	-0.82	0.59	-0.73	0.59	0.15	0.26	0.5	-0.4	0.66	0.44	-0.01	-0.61		1.0	0.53	0.76	-0.28	0.54	-0.47	-0.92	-0.92	-0.47
Short Term Debt	0.43	0.23	0.36	-0.51	-0.82	0.59	-0.73	0.59	0.15	0.26	0.5	-0.4	0.66	0.44	-0.01	-0.61	1.0		0.53	0.76	-0.28	0.54	-0.47	-0.92	-0.92	-0.47
Intangible Assets	0.59	0.54	0.43	-0.48	-0.81	0.49	-0.33	0.49	0.72	0.57	0.55	0.48	0.7	0.44	0.52	-0.97	0.53	0.53		0.82	0.46	0.45	-0.14	-0.69	-0.74	-0.14
Common Stock	0.79	0.35	0.68	-0.77	-0.96	0.79	-0.59	0.79	0.66	0.39	0.79	0.09	0.87	0.75	0.12	-0.84	0.76	0.76	0.82		0.1	0.34	-0.32	-0.92	-0.91	-0.32
Property Plant Equipment	0.09	0.72	-0.1	0.19	-0.16	-0.21	0.26	-0.21	0.73	0.72	-0.05	0.73	0.21	-0.06	0.83	-0.41	-0.28	-0.28	0.46	0.1		0.33	0.2	0.14	0.05	0.2
Other Current Liab	-0.11	0.77	-0.31	0.18	-0.47	-0.12	-0.34	-0.12	0.21	0.77	-0.14	-0.17	0.32	-0.2	0.69	-0.44	0.54	0.54	0.45	0.34	0.33		-0.04	-0.38	-0.52	-0.04
Other Liab	-0.49	-0.04	-0.48	0.36	0.37	-0.53	0.28	-0.53	-0.12	-0.05	-0.52	0.03	-0.54	-0.48	0.18	0.32	-0.47	-0.47	-0.14	-0.32	0.2	-0.04		0.42	0.29	1.0
Property Plant And Equipment Net	-0.69	-0.26	-0.61	0.74	0.94	-0.78	0.71	-0.78	-0.42	-0.3	-0.73	0.15	-0.79	-0.67	-0.01	0.76	-0.92	-0.92	-0.69	-0.92	0.14	-0.38	0.42		0.97	0.42
Non Currrent Assets Other	-0.57	-0.39	-0.45	0.61	0.94	-0.64	0.7	-0.64	-0.43	-0.43	-0.6	0.17	-0.72	-0.54	-0.16	0.77	-0.92	-0.92	-0.74	-0.91	0.05	-0.52	0.29	0.97		0.29
Other Assets	-0.49	-0.04	-0.48	0.36	0.37	-0.53	0.28	-0.53	-0.12	-0.05	-0.52	0.03	-0.54	-0.48	0.18	0.32	-0.47	-0.47	-0.14	-0.32	0.2	-0.04	1.0	0.42	0.29

Click cells to compare fundamentals

Telo Genomics Account Relationship Matchups

Telo Genomics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.2M	3.8M	2.8M	2.9M	3.4M	3.5M
Total Current Liabilities	353.4K	113.7K	190.1K	280.4K	322.4K	362.7K
Total Stockholder Equity	775.3K	3.7M	2.6M	2.6M	3.0M	3.2M
Net Debt	(881.0K)	(3.6M)	(2.7M)	(2.6M)	(2.4M)	(2.3M)
Retained Earnings	(19.1M)	(20.2M)	(22.3M)	(25.1M)	(22.6M)	(21.5M)
Cash	921.0K	3.6M	2.7M	2.7M	3.1M	3.2M
Non Current Assets Total	131.4K	78.4K	46.7K	82.6K	74.4K	70.6K
Cash And Short Term Investments	921.0K	3.6M	2.7M	2.7M	3.1M	3.2M
Liabilities And Stockholders Equity	1.2M	3.8M	2.8M	2.9M	3.4M	3.5M
Other Stockholder Equity	5.6M	5.6M	5.8M	6.0M	6.9M	4.6M
Total Liab	393.4K	153.7K	230.1K	312.9K	359.8K	378.2K
Total Current Assets	1.0M	3.8M	2.8M	2.8M	3.3M	3.4M
Net Receivables	49.3K	96.7K	38.0K	63.8K	57.4K	67.7K
Common Stock Shares Outstanding	29.9M	46.9M	58.7M	60.2M	69.2M	72.6M
Net Tangible Assets	(1.0M)	643.9K	3.6M	2.6M	3.0M	3.1M
Accounts Payable	1.0M	353.4K	102.4K	190.0K	171.0K	162.5K
Common Stock	14.3M	18.2M	19.1M	21.7M	24.9M	13.3M
Property Plant Equipment	179.7K	115.0K	62.1K	22.9K	20.6K	19.6K
Property Plant And Equipment Net	115.0K	62.1K	30.3K	66.3K	59.6K	56.7K
Other Current Assets	67.1K	27.5K	55.6K	105.9K	121.8K	127.9K
Net Invested Capital	815.3K	3.7M	2.6M	2.6M	3.0M	1.7M
Net Working Capital	683.9K	3.6M	2.6M	2.6M	2.9M	3.1M
Capital Stock	14.3M	18.2M	19.1M	21.7M	24.9M	18.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Telo Stock Analysis

When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC